A Class Action Suits Moves RICO from Mobsters to Medicine
RICO, the Racketeer Influenced and Corrupt Organizations Act, was originally designed to prosecute organized crime. Today, it sits at the center of a ...
Outsmarting Resistance with Rhythm
Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at the cost of...
Editing Away Autoimmunity at the HLA Source
Human leukocyte antigen, or HLA, genes, help the immune system tell the difference between the body’s own tissues and outside threats. In some people,...
Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug developm...
Reprogramming Cancer from Within
Leukemia once threatened Aaron Viny’s life, but now it defines his mission. Diagnosed with acute lymphoblastic leukemia as a college student, he survi...
A Strategic Turn from Obesity to Cancer
When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead ...
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder ca...
Reprogramming T Cells to Cross the Brain’s Border
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platf...
A Billion-Dollar Bet on AI-First Drug Development
Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure ...
Finding New Targets on the Surface of Misfolded Proteins
Finding New Targets on the Surface of Misfolded One of the biggest hurdles in drug development is targeting proteins found in both healthy and disease...